[Effect of a new benzodiazepine derivative on experimental malignant melanomas].
It was found, that (+)cis-3,4-dimethoxy-10,11-dimethyl-6,6aR,7,8,13, 13aS-hexahydro-[I]-benzopyrano-[4,3-b]-1,5-benzodiazepine (ZIMET 54/79) increased the life span (ILS) of C57BL/6/Jena mice suffering from transplanted B16 melanoma (ip.) by 57% (9 times ip. 250 mg/kg) and 90% (9 times ip. 500 mg/kg) respectively. In B6D2F1/Bln mice with transplanted B16 melanoma there was no ILS registered when a dose of 100-500 mg/kg was applied (ip. and p.o.). Using the Harding Passey melanoma (B6D2F1/Bln mice) only 59% tumour volume inhibition (500 mg/kg) without ILS was obtained. Finally ZIMET 54/79 tested on AMel 3 hamster melanoma (strain Z3) decreased the mean tumour volume by 72% (125 mg/kg).
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008647:Mesocricetus; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D013329:Structure-Activity Relationship; D013997:Time Factors
D000970:Antineoplastic Agents; D001569:Benzodiazepines; C051784:ZIMET 54-79
Die Wirkung eines neuen Benzodiazepin-Derivates auf experimentelle maligne Melanome.